1. International Workshop on CLL: Chronic lymphocytic leukemia: recommendations for diagnosis, staging, and response criteria. International Workshop on Chronic Lymphocytic Leukemia. Ann Intern Med 110:236-238, 1989.

2. Cheson BD, Bennett JM, Grever M, et al.: National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87:4990-4997, 1996.

3. van Dongen JJM, Langerak AW, Brüggemann M, et al.: Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T cell receptor gene recombinations in suspect lymphoprolif-erations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17:2257-2317, 2003.

4. Rawstron AC, Kennedy B, Evans PA, et al.: Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 98:29-35, 2001.

5. Böttcher S, Ritgen M, Pott C, et al.: Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation. Leukemia 18:1637-1645, 2004.

6. Rawstron AC, Villamor N, Zehnder JL, et al.: International standardized approach to molecular and flow cytometric disease monitoring in CLL [abstract]. Blood 104:15, 2004.

7. Provan D, Bartlett-Pandite L, Zwicky C, et al.: Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 88:2228-2235, 1996.

8. Bosch F, Ferrer A, Lôpez-Guillermo A, et al.: Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol 119:976-984, 2002.

9. Moreton P, Kennedy B, Lucas G, et al.: Eradication of minimal residual disease (MRD) in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 23:2971-2979, 2005.

10. Cheson BD: Infectious and immunosuppresive complications of purine analog therapy. J Clin Oncol 13:2431-2448, 1995.

11. Rai KR, Sawitsky A, Cronkite EP, et al.: Clinical staging of chronic lymphocytic leukemia. Blood 46:219-234, 1975.

12. Binet JL, Auquier A, Dighiero G, et al.: A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48:198-206, 1981.

13. Rozman C, Bosch F, Montserrat E: Chronic lymphocytic leukemia: a changing natural history? Leukemia 11:775-778, 1997.

14. Molica S, Levato D: GAT is changing in the natural history of chronic lymphocytic leukemia? Haematologica 86:8-12, 2001.

15. Mauro FR, Foa R, Cerretti R, et al.: Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clincial, therapeutic, and prognostic features. Blood 95:2788-2792, 2000.

16. Kyasa MJ, Parrish RS, Schichman SA, Zent CS: Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma. Am JHematol 74:1-8, 2003.

17. Montserrat E: Assessing prognosis in patients with chronic lymphocytic leukemia a quarter of century after Rai and Binet staging systems. Ann Oncol 15:450-451, 2004.

18. Zent CS, Kay NE: Advances in the understanding of biology and prognosis in chronic lymphocytic leukemia. Curr Oncol Rep 5:348-354, 2004.

19. Döhner H, Stilgenbauer S, Benner A, et al.: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910-1916, 2000.

20. Döhner H, Stilgenbauer S, Döhner K, Bentz M, Lichter P: Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis. J Mol Med 77:266-281, 1999.

21. Cuneo A, Rigolin GM, Bigoni R, et al.: Chronic lympho-cytic leukemia with 6q- shows distinct haematological features and intermediate prognosis. Leukemia 18:476-483, 2004.

22. Friedenberg WR, Spencer SK, Musser C, et al.: Multi-drug resistance in chronic lymphocytic leukemia. Leuk Lymphoma 34:171-178, 1999.

23. Pepper C, Thomas A, Hidalgo de Quintana J, Davies S, Hoy Y, Bentley P: Pleiotropic drug resistance in B-cell chronic lymphocytic leukaemia-the role of Bcl-2 family disregulation. Leuk Res 1007-1014, 1999.

24. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK: Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848-1854, 1999.

25. Damle RN, Wasil T, Fais F, et al.: Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1840-1847, 1999.

26. Krober A, Seiler T, Benner A, et al.: V(H) mutation status, CD38 expression level, genomic aberrations, and prognosis in chronic lymphocytic leukemia. Blood 100:1410-1416, 2002.

27. Hamblin TJ, Orchad JA, Ibbotson RE, et al.: CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 99:1023-1029, 2002.

28. Crespo M, Bosch F, Villamor N, et al.: ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl

J Med 348:1764-1775, 2003.

29. Wiestner A, Rosenwald A, Barry TS, et al.: ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 101:4944-4951, 2003.

30. Orchad JA, Ibbotson RW, Davis Z, et al.: ZAP-70 expression and prognosis in chronic lymphocytic leukemia. Lancet 363:105-111, 2004.

31. Rassenti LZ, Huynh L, Toy TL, et al.: ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as predictor of disease progression in chronic lym-phocytic leukemia. N Engl J Med 351:893-901, 2004.

32. Heintel D, Kroemer E, Kienle D, et al.: High expression of activation-induced cytidine deaminase (AID) mRNA is associated with unmutated IgVH gene status and unfavorable cytogenetic aberrations in patients with chronic lymphocytic leukemia. Leukemia 4:756-762, 2004.

33. Richter MN: Generalized reticular cell sarcoma of lymph nodes associated with lymphatic leukemia. Am J Pathol 4:285-292, 1928.

34. Robertson LE, Pugh W, O'Brien S, et al.: Richter's syndrome: a report on 39 patients. J Clin Oncol 11:1985-1989, 1993.

35. Giles FJ, O'Brien SM, Keating MJ: Chronic lymphocytic leukemia in (Richter's) transformation. Semin Oncol 25:117-125, 1998.

36. Enno A, Catovsky D, O'Brien M, et al.: 'Prolymphocytoid' transformation of chronic lymphocytic leukemia. Br J Haematol 41:9-18, 1979.

37. Greene MH, Hoover RN, Fraumeni JF: Subsequent cancer in patients with chronic lymphocytic leukemia. A possible immunologic mechanism. J Natl Cancer Inst 61:337-340, 1978.

38. Hisada M, Biggar RJ, Greene MH, et al.: Solid tumors after chronic lymphocytic leukemia. Blood 98:1979-1981, 2001.

39. Morrison VA, Rai KR, Peterson BL, et al.: Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, Cancer and Leukemia Group B. J Clin Oncol 20:3878-3884, 2002.

40. Rozman C, Montserrat E, Vinolas N: Serum immunoglobulins in B-chronic lymphocytic leukaemia. Natural history and prognostic significance. Cancer 61:279-283, 1988.

41. Molica S: Infections in chronic lymphocytic leukemia: Risk factors, an impact on survival, and treatment. Leuk Lymphoma 13:203-214, 1994.

42. Weiss RB, Freiman J, Kweder SL, Diehl LF, Byrd JC: Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. J Clin Oncol 16:1885-1889, 1998.

43. Montserrat E, Alcala A, Parody R, et al.: A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone. Cancer 56:2369-2375, 1985.

44. Catovsky D, Fooks I, Richards S: Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex, and response to treatment in survival. A report from the MRC CLL 1 trial. Br J Haematol 72:141-149, 1989.

45. Keating MI, O'Brien S, Kantarjian H, et al.: Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 81: 2878-2884, 1993.

46. Esteve J, Villamor N, Colomer D, Montserrat E: Different clinical value of minimal residual disease after autolo-

gous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. Blood 99:1873-1874, 2002.

47. Mattson J, Uzuel M, Remberger M, et al.: Minimal residual disease is common after allogeneic stem cell transplantation in patients with B cell chronic lymphocytic leukemia and may be controlled by graft-versus-host disease. Leukemia 14:247-254, 2000.

48. Hallek M, Bergmann M, Emmerich B (for the German CLL Study Group). Chronic lymphocytic leukemia: updated recommendations on diagnosis and treatment. Onkologie 27:97-104, 2004.

49. Anonymous: Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. Br J Haematol 15:294-317, 2004.

Chapter 26

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook

Post a comment